# Sarfez Pharmaceuticals, Inc.: Phase 3 study withdrawn (Hypertension (HTN))

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Sarfez Pharmaceuticals, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease |
| NCT ID | NCT07223502 |
| Phase | Phase 3 |
| Status | withdrawn |
| Conditions | Hypertension (HTN) |
| Intervention types | drug |
| Site countries | United States |
| Posted | 2025-10-31 |
| Planned start | 2025-05-01 |
| Event | Withdrawn before enrolling |
| Event date | 2026-09-22 |
| Last update posted | 2026-09-22 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07223502). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.